JSC Russian Railways tr. Rossiyskie zheleznye dorogi ), is a Russian vertically integrated company, both managing infrastructure and operating freight and passenger train services. In 2012 it became one of the three largest transport companies in the world. The company was established on September 18, 2003, when a decree was passed to separate the railways from the Russian Ministry of the Means of Communication .Full name — Open Joint Stock Company Russian Railways with headquarters in Moscow at Novaya Basmannaya str., 2. The operating units of the central part of the staff are at Kalanchevskaya str., 35. The president of the company is Vladimir Yakunin since June 14, 2005. Wikipedia.
Kirillin M.,RAS Institute of Applied Physics |
Panteleeva O.,Russian Railways |
Yunusova E.,Nizhny Novgorod State Medical Academy |
Donchenko E.,Research Institute of Traumatology and Orthopedics |
Shakhova N.,RAS Institute of Applied Physics
Journal of Biomedical Optics | Year: 2012
An increase of infertility and chronic pelvic pains syndrome, a growing level of latent diseases of this group, as well as a stably high percentage (up to 25% for infertility and up to 60% for the chronic pelvic pains syndrome) of undetermined origin raises the requirement for novel introscopic diagnostic techniques. We demonstrate abilities of optical coherence tomography (OCT) as a complementary technique to laparoscopy in diagnostics of fallopian tubes pathologies. We have acquired OCT images of different parts of fallopian tubes in norm and with morphologically proven pathology. Based on comparative analysis of the OCT data and the results of histological studies, we have worked out the subjective OCT criteria for distinguishing between unaltered and pathologic tissues. The developed criteria are verified in blind recognition tests. Diagnostic efficacy of OCT diagnostics in the case ofpelvic inflammatory diseases has been statistically evaluated, and high diagnostic accuracy (88%) is shown. Basing of the subjective criteria, an attempt to develop independent criteria aimed for automated recognition of pathological states in fallopian tubes is undertaken. Enhanced diagnostic accuracy (96%) of the developed independent criteria is demonstrated. © 2012 Society of Photo-Optical Instrumentation Engineers (SPIE).
Sadykov S.S.,Vladimir State University |
Bulanova Y.A.,Vladimir State University |
Zakharova E.A.,Russian Railways
Computer Optics | Year: 2014
This paper proposes a technology of computer diagnosis of tumors in mammary gland of three main types: cyst, fibroadenoma, and breast cancer. It is noted that the use of such technology in the health care setting reduces the chance of missing a tumor when viewing mammograms, are at an early stage of development, but also minimizes the subjectivity of diagnosis. Work on a set of technologies studied real mammograms from MIAS database with known diagnoses. The results of experiments that show the possibility of using the developed based on this technology integrated cabinet in mammography as for general research and well as for screening.
Atkov O.Y.,Moscow State University |
Gorokhova S.G.,Moscow State University |
Sboev A.G.,National Research Nuclear University |
Generozov E.V.,Karpov Institute of Physical Chemistry |
And 3 more authors.
Journal of Cardiology | Year: 2012
The aim of this study was to develop an artificial neural networks-based (ANNs) diagnostic model for coronary heart disease (CHD) using a complex of traditional and genetic factors of this disease. The original database for ANNs included clinical, laboratory, functional, coronary angiographic, and genetic [single nucleotide polymorphisms (SNPs)] characteristics of 487 patients (327 with CHD caused by coronary atherosclerosis, 160 without CHD). By changing the types of ANN and the number of input factors applied, we created models that demonstrated 64-94% accuracy. The best accuracy was obtained with a neural networks topology of multilayer perceptron with two hidden layers for models included by both genetic and non-genetic CHD risk factors. © 2011 Japanese College of Cardiology.
Shaposhnikov D.,Russian Academy of Sciences |
Revich B.,Russian Academy of Sciences |
Gurfinkel Y.,Russian Railways |
Naumova E.,Tufts University
International Journal of Biometeorology | Year: 2014
Evidence of the impact of air temperature and pressure on cardiovascular morbidity is still quite limited and controversial, and even less is known about the potential influence of geomagnetic activity. The objective of this study was to assess impacts of air temperature, barometric pressure and geomagnetic activity on hospitalizations with myocardial infarctions and brain strokes. We studied 2,833 myocardial infarctions and 1,096 brain strokes registered in two Moscow hospitals between 1992 and 2005. Daily event rates were linked with meteorological and geomagnetic conditions, using generalized linear model with controls for day of the week, seasonal and long-term trends. The number of myocardial infarctions decreased with temperature, displayed a U-shaped relationship with pressure and variations in pressure, and increased with geomagnetic activity. The number of strokes increased with temperature, daily temperature range and geomagnetic activity. Detrimental effects on strokes of low pressure and falling pressure were observed. Relative risks of infarctions and strokes during geomagnetic storms were 1.29 (95 % CI 1.19-1.40) and 1.25 (1.10-1.42), respectively. The number of strokes doubled during cold spells. The influence of barometric pressure on hospitalizations was relatively greater than the influence of geomagnetic activity, and the influence of temperature was greater than the influence of pressure. Brain strokes were more sensitive to inclement weather than myocardial infarctions. This paper provides quantitative estimates of the expected increases in hospital admissions on the worst days and can help to develop preventive health plans for cardiovascular diseases. © 2013 ISB.
Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): A randomised, double-blind, placebo-controlled phase 3 trial
Petrylak D.P.,Yale Cancer Center |
Vogelzang N.J.,Us Oncology Research |
Vogelzang N.J.,Comprehensive Cancer Centers of Nevada |
Budnik N.,Russian Railways |
And 20 more authors.
The Lancet Oncology | Year: 2015
Background: Patients with metastatic castration-resistant prostate cancer have few treatment options. We investigated the safety and efficacy of lenalidomide, an immunomodulatory agent with anti-angiogenic properties, in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. Methods: In this randomised, double-blind, placebo-controlled, phase 3 study, we randomly assigned chemotherapy-naive patients with progressive metastatic castration-resistant prostate cancer in a 1:1 ratio to receive docetaxel (75 mg/m2) on day 1 and prednisone (5 mg twice daily) on days 1-21 and either lenalidomide (25 mg) or placebo once daily on days 1-14 of each 21 day treatment cycle. Permuted block randomisation was done with an interactive voice response system and stratified by Eastern Cooperative Oncology Group performance status, geographic region, and type of disease progression. Clinicians, patients, and investigators were masked to treatment allocation. The primary endpoint was overall survival. Efficacy analysis was by intention to treat. Patients who received at least one dose of study drug were included in the safety analyses. This study is registered with ClinicalTrials.gov, number NCT00988208. Findings: 1059 patients were enrolled and randomly assigned between Nov 11, 2009, and Nov 23, 2011 (533 to the lenalidomide group and 526 to the control group), and 1046 patients received study treatment (525 in the lenalidomide group and 521 in the placebo group). At data cutoff (Jan 13, 2012) after a median follow-up of 8 months (IQR 5-12), 221 patients had died: 129 in the lenalidomide group and 92 in the placebo group. Median overall survival was 17·7 months (95% CI 14·8-18·8) in the lenalidomide group and not reached in the placebo group (hazard ratio [HR] 1·53, 95% CI 1·17-2·00, p=0·0017). The trial was subsequently closed early due to futility. The number of deaths that occurred during treatment or less than 28 days since the last dose were similar in both groups (18 [3%] of 525 patients in the lenalidomide group vs 13 [2%] of 521 patients). 109 (21%) patients in the lenalidomide group and 78 (15%) in the placebo group died more than 28 days from last dose, mainly due to disease progression. At least one grade 3 or higher adverse event was reported in 381 (73%) of 525 patients receiving lenalidomide and 303 (58%) of 521 patients receiving placebo. Grade 3-4 neutropenia (114 [22%] for lenalidomide vs 85 [16%] for placebo), febrile neutropenia (62 [12%] vs 23 [4%]), diarrhoea (37 [7%] vs 12 [2%]), pneumonia (24 [5%] vs five [1%]), dyspnoea (22 [4%] vs nine [2%]), asthenia (27 [5%] vs 17 [3%]), and pulmonary embolism (32 [6%] vs seven [1%]) occurred more frequently in the lenalidomide group than in the placebo group. Interpretation: Overall survival with the combination of lenalidomide, docetaxel, and prednisone was significantly worse than with docetaxel and prednisone for chemotherapy-naive men with metastatic, castration-resistant prostate cancer. Further research with this treatment combination is not warranted. © 2015 Elsevier Ltd.